Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Nanostructured SBA-15 silica: An effective protective vehicle to oral hepatitis B vaccine immunization

Full text
Author(s):
Show less -
Scaramuzzi, Karina ; Tanaka, Gabriela D. ; Mariano Neto, Francisco ; Garcia, Paulo R. A. F. ; Gabrili, Joel J. M. ; Oliveira, Denise C. A. ; Tambourgi, Denise V. ; Mussalem, Juliana S. ; Paixao-Cavalcante, Danielle ; D'Azeredo Orlando, Marcos T. ; Botosso, Viviane F. ; Oliveira, Cristiano L. P. ; Fantini, Marcia C. A. ; Sant'Anna, Osvaldo A.
Total Authors: 14
Document type: Journal article
Source: Nanomedicine-Nanotechnology Biology and Medicine; v. 12, n. 8, p. 2241-2250, NOV 2016.
Web of Science Citations: 4
Abstract

Due to its physicochemical properties, nanostructured mesoporous SBA-15 silica shows great potential as a vaccine adjuvant. This study evaluated the capacity of SBA-15 to encapsulate/adsorb the recombinant purified HBsAg from the Hepatitis B virus and the immunoresponsiveness of mice orally immunized with HBsAg inside SBA-15. A simulation of small angle X-ray scattering experimental results, together with the nitrogen adsorption isotherms data, allowed to determine the appropriate mass ratio of HBsAg: SBA-15, indicating antigen encapsulation into SBA-15 macroporosity. This was also evaluated by bicinchoninic acid assay and gel electrophoresis. The recruitment of inflammatory cells, an increase in production of specific antibodies, and the non-influence of silica on TH1 or TH2 polarization were observed after oral immunization. Besides, SBA-15 enhanced the phagocytosis of ovalbumin by dendritic cells, an important key to prove how this adjuvant works. Thus, it seems clear that the nanostructured SBA-15 is an effective and safe adjuvant for oral immunizations. (C) 2016 Elsevier Inc. All rights reserved. (AU)

FAPESP's process: 13/07467-1 - CeTICS - Center of Toxins, Immune-Response and Cell Signaling
Grantee:Hugo Aguirre Armelin
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC